Clinical trial / 2007
Oral resveratrol was safe up to 5 g, but peak plasma levels were lower than concentrations typically required for in vitro cancer chemopreventive effects.
A phase I study evaluated single oral doses of resveratrol (0.5, 1, 2.5, or 5 g) in 10 healthy volunteers per dose level. Administration did not cause serious adverse events. Peak plasma levels of resveratrol at the 5 g dose were 539 +/- 384 ng/mL (2.4 micromol/L), occurring 1.5 hours post-dose, while peak levels of metabolites were 3- to 8-fold higher. The authors note that because in vitro cancer chemopreventive effects require at least 5 micromol/L, high-dose resveratrol might be insufficient to elicit systemic levels commensurate with efficacy, though conjugate metabolites warrant investigation.
- Study type
- Phase I dose escalation pharmacokinetic study
- Who was studied
- 40 healthy volunteers (10 per dose level)
- What was measured
- Safety and plasma and urine pharmacokinetics of resveratrol and its metabolites
THE PAPER
Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.
Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE. Cancer Epidemiol Biomarkers Prev, 2007.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.